77 Pilocytic astrocytomas (PAs), rare, slow-growing brain tumours primarily affecting young children, have become a focal point in neuro-oncology research as scientists seek to enhance diagnosis and treatment protocols. Though classified as low-grade gliomas by the World Health Organization, recent studies highlight a complex landscape of molecular variants, each influencing prognosis and therapeutic options. The findings were published in the journal Oncology Letters. As the most common paediatric brain tumour, pilocytic astrocytomas predominantly arise in the cerebellum. Symptoms often relate to mass effects in the brain, including headaches, balance issues, and changes in behaviour or vision. PAs are distinguished by their characteristic cystic appearance with a small nodule, visible on magnetic resonance imaging (MRI). This diagnostic hallmark, however, is shared by other tumours, creating a need for precise differentiation. While PAs typically exhibit a favourable prognosis, location and patient age can significantly impact outcomes. Surgical resection, particularly when complete, remains the primary treatment, offering potential curative results. For certain patients, particularly young children, chemotherapy is considered over radiation to mitigate the risk of long-term developmental issues. Molecularly, PAs are notably marked by alterations in the MAPK pathway, specifically the BRAF gene. The most common of these, a fusion between KIAA1549 and BRAF, is a recognised marker in paediatric PAs, while other rare mutations add layers of complexity. This molecular diversity not only complicates treatment but also informs prognosis, as certain mutations are associated with higher recurrence rates and, in rare cases, malignant transformations. Precision-targeted therapies, including BRAF and MEK inhibitors, are showing promise in clinical trials, especially for cases unresponsive to traditional treatments. These inhibitors, designed to disrupt tumour growth by blocking MAPK pathway dysregulation, offer hope for enhanced disease management. The emergence of pilocytic astrocytomas with atypical molecular profiles has driven the need for comprehensive molecular analysis. For many patients, molecular profiling guides treatment choices, aiming to improve overall survival and reduce recurrence. The development of targeted therapies tailored to specific mutations marks a shift towards personalised treatment, underscoring the importance of multidisciplinary approaches in treating this rare tumour. While conventional treatment protocols remain the standard, evolving research in genetic and epigenetic characteristics holds potential for long-term improvements in patient outcomes. Pilocytic astrocytomas, while largely treatable, represent a complex neuro-oncological challenge. Advances in molecular profiling and targeted treatments are setting the stage for refined, personalised care, improving the outlook for children affected by this tumour.